Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | GRB2 | P62993 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481457 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL18511382 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL44052 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL29478416 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL44051 | 1.00 | SLC7A5 (0.62) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL23013168 | 0.98 | SLC7A5 (0.60) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL29481456 | 0.98 | SLC7A5 (0.60) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL28025299 | 0.98 | SLC7A5 (0.60) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL23013165 | 0.98 | SLC7A5 (0.60) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL22557028 | 0.92 | SLC7A5 (0.54) | SLC7A5PTGS1KDM4EUSP2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | claimed |
| EP-4358989-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2022271810-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-29 | — | — | WO | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-11-27 | — | — | US | disclosed |
| WO-2025245483-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250325469-A1 | Inhibitors of atp synthase - cosmetic and therapeutic uses | FORREST MICHAEL DAVID (GB) | 2025-10-23 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6514997-B2 | Block the activity of picornaviral 3C protease | AGOURON PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0954596-A1 | ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF $i(TAXUS) SPECIES | PHYTON, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997044476-A1 | ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF TAXUS SPECIES | PHYTON, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SLC7A5 1405/4885PTGS1 1907/4885KDM4E 848/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SLC7A5 1050/4885PTGS1 2516/4885KDM4E 2142/4885 |
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | KRAS, HRAS, NRAS | SLC7A5 2938/4885PTGS1 3299/4885KDM4E 4608/4885 |
| US-20250325469-A1 | Inhibitors of atp synthase - cosmetic and therapeutic uses | ATP5F1A, ATP5F1B, ATP5ME | SLC7A5 470/4885PTGS1 1055/4885KDM4E 4143/4885 |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | SLC7A5 3338/4885PTGS1 1739/4885KDM4E 2980/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | SLC7A5 1741/4885PTGS1 3808/4885KDM4E 2895/4885 |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | MC4R, GPR119, MC2R | SLC7A5 2654/4885PTGS1 1751/4885KDM4E 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.